Sunday 11 October 2026
Export all RLYB data to Excel Powerpack
Rallybio Corporation
RLYB Healthcare Biotechnology
In the quarter to June 2026, revenue was flat, EPS grew 535.2% and free cash flow grew 648.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
17.02
0.03
+0.18%
Follow RLYB
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 68.88 | 36.32 | 13.76 | 6.73 | 1.76 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 206.24 | 127.12 | 79.00 | 27.68 | 8.64 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 28 | 35 | 41 | 43 | 25 | 14 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.06 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | 1 | 1 | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | 100.00 | 100.00 | |||||
| EBT | — | — | — | (17) | (25) | (46) | (66) | (73) | (56) | (8) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (8,732.08) | (944.52) | |||||
| Net income | — | 0 | — | (18) | (26) | (47) | (67) | (75) | (58) | (9) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | (3) | (1) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.12 | 0.15 | ||||
| Earnings | — | — | — | (0.55) | (12.17) | (14.72) | (16.72) | (14.72) | (10.64) | (1.59) | |||||
| Cash flow | — | — | — | (0.47) | (10.14) | (14.27) | (14.40) | (11.92) | (9.05) | (5.30) | |||||
| Capex | — | — | — | 0.00 | (0.06) | (0.10) | (0.01) | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.47) | (10.20) | (14.38) | (14.42) | (11.92) | (9.05) | (5.30) | |||||
| Book value | — | — | — | 0.52 | 62.57 | 55.05 | 42.57 | 21.00 | 11.33 | 10.29 | |||||
| Shares, m | — | — | — | 32 | 2 | 3 | 4 | 5 | 5 | 6 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | 0.00 | 0.00 | ||||
| P/S | — | — | — | — | — | — | — | — | 0.00 | 36.02 | |||||
| P/B | — | — | — | — | — | — | — | — | 0.68 | 0.53 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | 0.00 | (27.77) | |||||
| EV/FCF | — | — | — | — | — | — | — | — | 0.48 | 0.80 | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (15) | (22) | (46) | (57) | (60) | (49) | (30) | ||||
| Capex | — | — | — | 0 | 0 | 0 | 0 | 0 | — | — | |||||
| Free cash flow | — | — | — | (15) | (22) | (46) | (57) | (60) | (49) | (30) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 17 | 135 | 174 | 169 | 106 | 62 | 57 | ||||
| Total debt | — | — | — | — | — | — | 1 | — | — | — | |||||
| Net debt | — | — | — | (19) | (140) | (175) | (169) | (110) | (66) | (55) | |||||
| Shareholders’ equity | — | — | — | 17 | 136 | 176 | 169 | 106 | 62 | 58 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (162.57) | (32.36) | (29.02) | (36.76) | (50.37) | (62.89) | (13.77) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | (10,645.52) | (13,135.45) | 0.00 | 0.00 | (641.77) | |||||
| ROE | — | — | — | 0.00 | (45.71) | (30.17) | (38.65) | (54.13) | (68.85) | (15.01) | |||||
Negative figures in brackets.
Fiscal years to Dec 2025 · latest quarter Mar 2026
Charts ten years each
Rallybio Corporation vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| OKUR OnKure Therapeutics, Inc. | $93.2M | — (loss-making) | — | — | n/m | +22.05% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ATRA Atara Biotherapeutics, Inc. | $92.6M | — (loss-making) | — (loss-making) | −96.42% (below 0%: shrinking) | n/m | +52.10% (above 0%: growing) | 69.68% | (749.21%) | Compare |
| VXRT VAXART, INC. | $92.4M | 2.8× | 2.1× | −31.58% (below 0%: shrinking) | n/m | +117.38% (above 0%: growing) | 100.00% | (48.45%) | Compare |
| EQ Equillium, Inc. | $91.3M | — (loss-making) | — (loss-making) | −52.32% (below 0%: shrinking) | n/m | −38.67% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| CLLS Cellectis S.A. | $90.4M | — (loss-making) | — | −62.05% (below 0%: shrinking) | n/m | −36.95% (below 0%: shrinking) | 100.00% | (340.69%) | Compare |
| RLYB Rallybio Corporation | $90.2M | 2.1× | — (loss-making) | 0.00% | n/m | +648.02% (above 0%: growing) | 100.00% | 0.00% | |
| NMRA Neumora Therapeutics, Inc. | $90.2M | — (loss-making) | — | — | n/m | +24.45% (above 0%: growing) | 0.00% | 0.00% | Compare |
| MIST Milestone Pharmaceuticals Inc. | $88.7M | — (loss-making) | — (loss-making) | −62.73% (below 0%: shrinking) | n/m | −80.81% (below 0%: shrinking) | 94.28% | (4,584.97%) | Compare |
| ICCC ImmuCell Corporation | $88.6M | 114× | — (loss-making) | +11.50% (above 0%: growing) | +233.33% (above 0%: growing) | +54.86% (above 0%: growing) | 33.92% | 26.93% | Compare |
| Median of peers | $90.9M | — | — | −57.18% | — | +23.25% | 81.98% | (24.22%) |
Rallybio Corporation (RLYB) key facts
- Rallybio Corporation (RLYB) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 9, 2026, RLYB traded at $17.02, a market capitalization of $90.2 million.
- Return on equity was −15.0% and debt-to-equity 0.00.
- Its Altman Z-score is −3.12 (distress zone) for fiscal 2025.